<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02676063</url>
  </required_header>
  <id_info>
    <org_study_id>DCIC1416</org_study_id>
    <nct_id>NCT02676063</nct_id>
  </id_info>
  <brief_title>Long Term Prognostic of Neonatal Hypoxic Ischemic Encephalopathy With Hypothermia Treatment</brief_title>
  <acronym>LyTONEPAL</acronym>
  <official_title>Long Term Prognostic of Neonatal Hypoxic Ischemic Encephalopathy in the Era of Neuroprotective Treatment With Hypothermia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate neonatal characteristics, and biological and clinical&#xD;
      investigations as predictive factors of death, or of severe and moderate neurodevelopmental&#xD;
      disability at 3 years, in a large population-based cohort of full-term and late preterm&#xD;
      neonates with moderate or severe HIE.&#xD;
&#xD;
      Contrary to most previous studies which have often analyzed the accuracy of one factor among&#xD;
      all other clinical investigations, the investigators objective's is to seek a relevant&#xD;
      combination of several factors among the following list:&#xD;
&#xD;
        -  Neonatal characteristics: gestational age and birthweight, maternal disease, acute&#xD;
           intrapartum event, delivery mode, acidosis, neurological examination, place of birth and&#xD;
           neonatal transfer&#xD;
&#xD;
        -  Laboratory investigations: pH, lactates and new biological markers as detailed below&#xD;
&#xD;
        -  Clinical investigations: aEEG, EEG, MRI, diffusion-weighted MRI&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypoxic-ischemic encephalopathy (HIE) is a rare neonatal condition affecting about 1‰ births&#xD;
      and with a high rate of death and severe neurological disability despite significant&#xD;
      improvement of the management of this illness in the last ten years. During the first hours&#xD;
      and days of life, different examinations are made by neonatologists to guide decisions about&#xD;
      the management of HIE and to provide information to families. Nevertheless, better knowledge&#xD;
      about the early and late predictive factors of long-term severe and moderate&#xD;
      neurodevelopmental outcomes is badly needed.&#xD;
&#xD;
      This study is a prospective national observational population-based study involving all level&#xD;
      III intensive care units in France.&#xD;
&#xD;
      This population-based cohort study will be performed including all moderate or severe cases&#xD;
      of HIE, occurring between 34 and 42 completed weeks gestation in newborns admitted to a&#xD;
      neonatal intensive care unit of the participating French regions. Children will be&#xD;
      followed-up until the age of 3 years.&#xD;
&#xD;
      Participating centers will be invited to adhere to current HIE management guidelines and/or&#xD;
      clinical investigations considered optimal to date, to ensure standardize clinical practice.&#xD;
      The study will ensure high quality data collection.&#xD;
&#xD;
      About indications, timing and characteristics of treatments and investigations will be&#xD;
      elaborated by the scientific committee during the preparation stage of the cohort study. This&#xD;
      professional advice will have the double advantage of enabling us to record more homogeneous&#xD;
      and high-quality data, and to standardize and improve clinical management and investigations&#xD;
      among newborns with HIE.&#xD;
&#xD;
      Within this main study, an ancillary study will be performed by 21 centers to address the&#xD;
      first secondary objective (predictive value of very early - first 6 hours of life -&#xD;
      neurological examination and biological investigations, including specific new biomarkers&#xD;
      such as Interleukin-6, Metalloproteinase-9, TIMP-1, Albumin modified by hypoxia, troponin I,&#xD;
      acylcarnitins and amino acids).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is a combined criterion : death, neurodevelopmental disabilities in survivors</measure>
    <time_frame>between birth and 3 years of age</time_frame>
    <description>A combined criterion which includes:&#xD;
Death between birth and 3 years of age&#xD;
Neurodevelopmental disabilities in survivors, defined as :&#xD;
o Severe disabilities&#xD;
Intellectual impairment with a mental score &gt;2SD below the mean or &lt;70 (ASQ)&#xD;
Or Cerebral palsy with a Gross Motor Function level of 3-5 according to the GMFCS&#xD;
Or bilateral blindness (vision &lt;20/200 acuity)&#xD;
Or deafness requiring amplification (&gt;60dB)and/&#xD;
Or a persistent disorder defined as recurrent seizures after discharge from neonatal intensive care requiring anti-convulsion therapy at the examination time point&#xD;
o Moderate disabilities&#xD;
Intellectual impairment with a mental score &gt;1SD below the mean or 70 to 84 (ASQ)&#xD;
Cerebral palsy with a Gross Motor Function level of 1 or 2 according to the GMFCS&#xD;
Or hearing impairment requiring no amplification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>First secondary objective : The relevance of specific new biomarkers : Protein levels (IL-6, MMP-9, TIMP-1, Albumine modified by hypoxia, troponine I), acylcarnitins and amino acids.</measure>
    <time_frame>before H6 and at 3 days</time_frame>
    <description>The biologist will evaluate the relevance of specific new biomarkers :&#xD;
Protein levels (IL-6, MMP-9, TIMP-1, Albumine modified by hypoxia, troponine I) unites will be determined using an ELISA&#xD;
the measurement of acylcarnitins and amino acids by tandem liquid phase chromatography coupled with mass spectroscopy.&#xD;
The analyses will be blinded and centralized to Reims University laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second secondary objective: the predictive value of clinical investigations during the first weeks of life and treatments.</measure>
    <time_frame>first week, At 18 months and 3 years of age</time_frame>
    <description>To analyze the predictive value of clinical investigations during the first weeks of life and treatments, including cooling:&#xD;
for normal outcomes (absence of death, any disability, any epilepsy or any need for physiotherapy, orthophonist or psychologist or other measures of reeducation), moderate or severe neurodevelopmental disabilities, and death&#xD;
At 18 months and 3 years of age&#xD;
In this part, we will assess the ability of a normal developmental assessment at 18 months to predict survival free of disability or retardation at 3 years. This information will be useful in the future to define different strategies of follow up according to the assessment at 18 months of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Third secondary objective : Number and percentage of participants with cooling.</measure>
    <time_frame>birth</time_frame>
    <description>The third secondary objective is analyzed thanks to :&#xD;
number of patients with method of cooling : Criticool, tecotherm, craft, other&#xD;
duration of cooling in hours&#xD;
number of severe or modere HIE according to the Sarnat classification&#xD;
time to initiate cooling in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fourth secondary objective : Number and percentage of various obstetrical conditions leading to the worse outcomes</measure>
    <time_frame>birth</time_frame>
    <description>Number and percentage of :&#xD;
Maternal pyrexia,&#xD;
a persistent occipito-posterior position,&#xD;
an acute intrapartum event (hemorrhage, maternal convulsions, rupture of uterus, snapped cord, and birth of baby before arrival at obstetric facility),&#xD;
an instrumental vaginal delivery&#xD;
an emergency caesarean section</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Ischemic-Hypoxic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>neonatal Hypoxic Ischemic encephalopathy</arm_group_label>
    <description>moderate or severe HIE among term and late preterm newborn</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This study will be performed on all moderate or severe cases of hypoxic ischemic&#xD;
        encephalopathyhie, occurring between 34 and 42 completed weeks gestation in newborns&#xD;
        admitted to a neonatal intensive care unit of the participating French regions. Children&#xD;
        will be followed-up until the age of 3 years.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants born at a gestational age of 34 weeks or more;&#xD;
&#xD;
          -  Presenting early neurological distress with clinical signs of moderate to severe HIE&#xD;
             at a standardized neurologic examination performed by a senior examiner:&#xD;
&#xD;
               -  Moderate HIE: lethargy, hyper-reflexia, miosis, bradycardia, seizures, hypotonia&#xD;
                  with weak suck and Moro reflex&#xD;
&#xD;
               -  Severe HIE: stupor, flaccidity, small to mid-position pupils that react poorly to&#xD;
                  light, reduced stretch reflexes, hypothermia or no Moro reflex&#xD;
&#xD;
          -  With criteria for asphyxia:&#xD;
&#xD;
               -  pH of 7.0 or less or a base deficit of 16 mmol per liter or more in a sample of&#xD;
                  umbilical-cord blood or any blood sampled in the first hour after birth.&#xD;
&#xD;
               -  If, during this interval, the pH is between 7.01 and 7.15, base deficit is&#xD;
                  between 10 and 15.9 mmol per liter, or blood gas is not available, additional&#xD;
                  criteria will be required. These include:&#xD;
&#xD;
               -  an acute perinatal event (e.g., late or variable decelerations, cord prolapse,&#xD;
                  cord rupture, uterine rupture, maternal trauma, hemorrhage, or cardiorespiratory&#xD;
                  arrest)&#xD;
&#xD;
               -  or an abrupt change in fetal heart rate (FHR), defined as a persistent abnormal&#xD;
                  FHE after a period of normal tracing: bradycardia or prolonged deceleration,&#xD;
                  persistent variable decelerations, persistent late decelerations, and reduced&#xD;
                  heart variability&#xD;
&#xD;
               -  or either a 10-minute Apgar score of 5 or less or assisted ventilation initiated&#xD;
                  at birth and continued for at least 10 minutes.&#xD;
&#xD;
          -  Written parental informed consent&#xD;
&#xD;
          -  Covered by the French social security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Congenital malformations&#xD;
&#xD;
          -  Chromosomal disorders&#xD;
&#xD;
          -  Congenital neuromuscular disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry DEBILLON, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Besancon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Clermond-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi Creteil</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU FORT de France</name>
      <address>
        <city>Fort De France</city>
        <zip>97200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chru Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu La Miletrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Reims</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU St Denis</name>
      <address>
        <city>Saint-Denis De La Réunion</city>
        <zip>97400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU St Pierre</name>
      <address>
        <city>Saint-Pierre</city>
        <zip>97410</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Volpe JJ. Neonatal encephalopathy: an inadequate term for hypoxic-ischemic encephalopathy. Ann Neurol. 2012 Aug;72(2):156-66. doi: 10.1002/ana.23647.</citation>
    <PMID>22926849</PMID>
  </reference>
  <reference>
    <citation>Use and abuse of the Apgar score. Committee on Fetus and Newborn, American Academy of Pediatrics, and Committee on Obstetric Practice, American College of Obstetricians and Gynecologists. Pediatrics. 1996 Jul;98(1):141-2.</citation>
    <PMID>8668389</PMID>
  </reference>
  <reference>
    <citation>Fenichel GM. Hypoxic-ischemic encephalopathy in the newborn. Arch Neurol. 1983 May;40(5):261-6. Review.</citation>
    <PMID>6405725</PMID>
  </reference>
  <reference>
    <citation>Levene ML, Kornberg J, Williams TH. The incidence and severity of post-asphyxial encephalopathy in full-term infants. Early Hum Dev. 1985 May;11(1):21-6.</citation>
    <PMID>4006822</PMID>
  </reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>September 28, 2015</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2016</study_first_posted>
  <last_update_submitted>June 4, 2018</last_update_submitted>
  <last_update_submitted_qc>June 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>predictive factors</keyword>
  <keyword>neurodevelopmental disabilities</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
    <mesh_term>Hypoxia, Brain</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

